BDBM118134 US10017516, Compound 3::US9682983, 3

SMILES C1CN(CCN1)c1ccc(nc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12

InChI Key InChIKey=QCXBJMRMYRQRCV-UHFFFAOYSA-N

Data  12 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 12 hits for monomerid = 118134   

TargetSerine/threonine-protein kinase receptor R3(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM118134(US9682983, 3 | US10017516, Compound 3)
Affinity DataIC50: 27nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2-6...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2018
Entry Details
Go to US Patent

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM118134(US9682983, 3 | US10017516, Compound 3)
Affinity DataIC50: 16nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2-6...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2018
Entry Details
Go to US Patent

TargetBone morphogenetic protein receptor type-1A(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM118134(US9682983, 3 | US10017516, Compound 3)
Affinity DataIC50: 278nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2-6...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2018
Entry Details
Go to US Patent

TargetActivin receptor type-1B(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM118134(US9682983, 3 | US10017516, Compound 3)
Affinity DataIC50: 3.68E+3nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2-6...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2018
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM118134(US9682983, 3 | US10017516, Compound 3)
Affinity DataIC50: 8.19E+3nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2-6...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2018
Entry Details
Go to US Patent

TargetBone morphogenetic protein receptor type-1B(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM118134(US9682983, 3 | US10017516, Compound 3)
Affinity DataIC50: 823nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2-6...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2018
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase receptor R3(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM118134(US9682983, 3 | US10017516, Compound 3)
Affinity DataIC50: 27nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM118134(US9682983, 3 | US10017516, Compound 3)
Affinity DataIC50: 16nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetBone morphogenetic protein receptor type-1A(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM118134(US9682983, 3 | US10017516, Compound 3)
Affinity DataIC50: 278nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetActivin receptor type-1B(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM118134(US9682983, 3 | US10017516, Compound 3)
Affinity DataIC50: 3.68E+3nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM118134(US9682983, 3 | US10017516, Compound 3)
Affinity DataIC50: 8.19E+3nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetBone morphogenetic protein receptor type-1B(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM118134(US9682983, 3 | US10017516, Compound 3)
Affinity DataIC50: 823nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent